<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-04-30">April 30, 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Markus</forename><surname>Wallner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Cardiology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Lewis Katz School of Medicine</orgName>
								<orgName type="institution" key="instit1">Cardiovascular Research Center</orgName>
								<orgName type="institution" key="instit2">Temple University</orgName>
								<address>
									<postCode>19140 PA</postCode>
									<settlement>Philadelphia</settlement>
									<country>United States of America</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mounir</forename><surname>Khafaga</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Cardiology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Ewald</forename><surname>Kolesnik</surname></persName>
							<email>ewald.kolesnik@medunigraz.at</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Cardiology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Aris</forename><surname>Vafiadis</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Cardiology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerold</forename><surname>Schwantzer</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute for Medical Informatics, Statistics, and Documentation</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Deborah</forename><forename type="middle">M</forename><surname>Eaton</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Lewis Katz School of Medicine</orgName>
								<orgName type="institution" key="instit1">Cardiovascular Research Center</orgName>
								<orgName type="institution" key="instit2">Temple University</orgName>
								<address>
									<postCode>19140 PA</postCode>
									<settlement>Philadelphia</settlement>
									<country>United States of America</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pero</forename><surname>Curcic</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Division of Cardiac Surgery</orgName>
								<orgName type="department" key="dep2">Department of Surgery</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Köstenberger</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Pediatric Cardiology</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Igor</forename><surname>Knez</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Division of Cardiac Surgery</orgName>
								<orgName type="department" key="dep2">Department of Surgery</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><forename type="middle">P</forename><surname>Rainer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Cardiology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Pichler</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Clinical Oncology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Burkert</forename><surname>Pieske</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Cardiology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Department of Internal Medicine and Cardiology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of Internal Medicine and Cardiology</orgName>
								<orgName type="institution">German Heart Center</orgName>
								<address>
									<postCode>13353</postCode>
									<settlement>Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dirk</forename><forename type="middle">Von</forename><surname>Lewinski</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Cardiology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<postCode>8036</postCode>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-04-30">April 30, 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">E139A5A9E20A91B436BF4C75A3A6CDC2</idno>
					<note type="submission">Received: March 06, 2017 Accepted: April 14, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:15+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>prostate cancer</term>
					<term>hormone therapy</term>
					<term>cardiac disease models</term>
					<term>heart failure</term>
					<term>istaroxime</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The current gold standard for prostate cancer treatment is androgen deprivation therapy and antiandrogenic agents.</s><s>However, adverse cardiovascular events including heart failure can limit therapeutic use.</s><s>Istaroxime, which combines Na + -K + -ATPase (NKA) inhibition with sarco/endoplasmic reticulum Ca 2+ -ATPase 2a (SERCA2a) stimulation, has recently shown promising anti-neoplastic effects in prostate cancer (PC) models and may also improve cardiac function.</s><s>Considering the promising anticancer effects of istaroxime, we aimed to assess its functional effects on human myocardium.</s></p><p><s>Results: Istaroxime and strophanthidin elicited dose-dependent positive inotropic effects with a decline in developed force at supraphysiological concentrations in human atrial, nonfailing, and failing ventricular (ToF) myocardium.</s><s>Diastolic force and RT50% did not change after exposure to both drugs.</s><s>The maximal developed force in our in-vitro model of heart failure (ToF) was significantly higher after istaroxime administration.</s><s>Such a difference did not occur in atrial or nonfailing ventricular trabeculae and was not applicable to the diastolic force.</s></p><p><s>Materials and Methods: Human atrial and ventricular trabeculae were isolated from nonfailing hearts and hearts of infants with tetralogy of Fallot (ToF), which were used as an in-vitro model of heart failure.</s><s>The samples were electrically stimulated and treated with increasing concentrations of istaroxime and strophanthidin (10 nM-1 µM).</s><s>Systolic and diastolic force development and relaxation parameters (RT50%) were analyzed.</s></p><p><s>Conclusions: Combined NKA inhibition/SERCA2a stimulation increases contractility in atrial, nonfailing, and failing myocardium.</s><s>Considering that heart failure is a potential side effect of current PC treatments, especially in elderly patients, istaroxime might combine beneficial cardiac and anti-cancer properties.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Prostate cancer (PC) is the most common malignant disease in elderly men in western countries <ref type="bibr" target="#b0">[1]</ref>.</s><s>There has been an increase in the availability of diagnostic tools for PC, such as prostate-specific-antigen-based screening tests, and advancements in therapeutics that have resulted in a decline in the total number of fatal PC rates <ref type="bibr" target="#b1">[2]</ref>.</s><s>Despite the improvements in both diagnosing and treating the disease, it is still associated with moderate mortality rates, partially attributed to stable rates of fatal PC in younger men <ref type="bibr" target="#b2">[3]</ref>.</s><s>A study using the "Surveillance, Epidemiology, and End Results (SEER)" data of the United States found that PC accounts for approximately 19% of all newly diagnosed cases of cancer in men and approximately 8% of all deaths due to cancer in men in 2017 <ref type="bibr" target="#b0">[1]</ref>.</s><s>The study also reported a median age at time of diagnosis of 66 years and a median age at time of death of 80 years, underlining the age-associated nature of this disease <ref type="bibr" target="#b3">[4]</ref>.</s><s>The current gold-standard conservative approach for PC is androgen deprivation therapy, which is used as an adjunctive treatment strategy in localized high-risk PC or as a continuous treatment for metastatic PC patients.</s><s>In addition, novel antiandrogens (enzalutamide) and androgen biosynthesis inhibitors (abiraterone) are approved in the setting of metastatic PC before and after docetaxel chemotherapy.</s><s>Furthermore, these agents are currently being investigated in clinical trials for their efficacy in a non-metastatic PC setting <ref type="bibr" target="#b4">[5]</ref>.</s><s>However, increased risk of cardiovascular diseases, such as coronary artery diseases, acute myocardial infarction and heart failure (HF), are reported as limiting side effects and contraindications for some of these drugs.</s><s>This may significantly limit their therapeutic use <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref>.</s></p><p><s>Istaroxime, a novel drug originally developed for treating HF, received attention for its potential antineoplastic effects.</s><s>Istaroxime inhibits Na+-K+-ATPase (NKA), like strophanthidin, and exerts additional stimulatory effects on the sarco/endoplasmic reticulum Ca 2+ -ATPase 2a (SERCA2a).</s><s>It has exhibited lusitropic and inotropic properties in experimental and early clinical studies <ref type="bibr" target="#b10">[11]</ref>.</s><s>Preclinical studies and clinical trials indicate that combining SERCA2a activation and NKA inhibition may increase contractility and facilitate active relaxation, improving systolic as well as diastolic heart function, both of which would be beneficial effects in the treatment of chronic HF <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>.</s><s>Early data from human studies have shown that istaroxime increases systolic blood pressure, decreases heart rate, decreases pulmonary capillary wedge pressure, and possibly improves diastolic function without increasing myocardial oxygen consumption or causing a significant change in ischemic or arrhythmic events <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref>.</s><s>However, larger clinical trials with the purpose of exploring the clinical usage of istaroxime in HF were never performed, thus guideline-based indications do not exist.</s></p><p><s>Although istaroxime may not make it to market as a HF drug, it continues to show potential as an anticancer drug.</s><s>Istaroxime showed promising anti-neoplastic effects in the cell lines of 9 different types of cancer and a reduction of tumor growth in vivo in PC xenograft models.</s><s>Furthermore, the authors of this study identified a putative crosstalk between the inhibition of NKA and membranebound androgen receptor and down-stream signaling <ref type="bibr" target="#b16">[17]</ref>.</s><s>This data fits well with the results of previous studies, which demonstrated that NKA inhibitors have a strong anti-neoplastic potential <ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref>.</s><s>Of note, HF and PC share risk factors such as age and hyperlipidaemia <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22]</ref>.</s><s>Since the cardiovascular complications of current androgen deprivation therapeutics can significantly limit their usage, evaluating the cardiovascular safety profiles of newly developed drugs is essential.</s></p><p><s>Therefore, we tested the functional effects of istaroxime on human nonfailing atrial and ventricular myocardium and a unique in-vitro model of heart failure with diastolic dysfunction.</s><s>This model is especially valuable considering that impaired relaxation is a common condition in many elderly patients who have HF with preserved ejection fraction.</s><s>For comparison, we performed experiments with the same conditions using the NKA inhibitor strophanthidin, as previous studies have already determined its functional impact on human myocardium <ref type="bibr" target="#b22">[23]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional effects of istaroxime and strophanthidin in human atrial myocardium</head><p><s>We assessed the effects of NKA inhibition alone (strophanthidin; n = 13 trabeculae) versus NKA inhibition combined with SERCA stimulation (istaroxime; n = 8 trabeculae) on developed force in human atrial trabeculae.</s><s>Increasing concentrations of strophanthidin increased the developed force with a maximum effect at 0.1 µM.</s><s>The developed force declined further as the concentration was increased.</s><s>Similarly, increasing concentrations of istaroxime (black circles) produced a positive inotropic effect with a maximum effect at 0.3 µM and subsequent force decline at higher concentrations (Figure <ref type="figure" target="#fig_0">1A</ref>).</s><s>Both strophanthidin and istaroxime slightly increased diastolic force compared to baseline in a dose-dependent manner with comparable kinetics of the curves (Figure <ref type="figure" target="#fig_0">1B</ref>).</s><s>Next, we performed force-frequency relationship (FFR) experiments by increasing stimulation frequencies stepwise (0.5-3.0Hz) before and after incubation with either istaroxime or strophantidin.</s><s>FFR results are shown in the supplement (Supplementary Figure <ref type="figure" target="#fig_0">1A-1D</ref>).</s><s>Similar effects between strophanthidin and istaroxime could be observed.</s><s>No arrhythmic events were detected for istaroxime or strophanthidin in any of the experiments www.impactjournals.com/oncotarget</s><s>performed.</s><s>The RT50%, a relaxation parameter, did not reveal any significant differences between istaroxime and strophanthidin in dose response relationship (DRR) or FFR experiments (Supplementary Figure <ref type="figure" target="#fig_2">3A-3C</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional effects of istaroxime and strophanthidin in human nonfailing ventricular myocardium</head><p><s>Next, we investigated the effects of istaroxime and strophanthidin in isolated ventricular trabeculae from human nonfailing donor hearts.</s><s>Analogous to our findings in atrial trabeculae, strophanthidin (n = 9 trabeculae) and istaroxime (n = 9 trabeculae) increased developed force in ventricular trabeculae (Figure <ref type="figure" target="#fig_0">1C</ref>) in a dose-dependent and comparable manner.</s><s>Maximum effect on systolic force was seen at 0.3 µM for both substances.</s><s>Developed force declined as the concentration was increased up to 1 µM. Figure <ref type="figure" target="#fig_0">1D</ref> shows the effect of strophanthidin and istaroxime on diastolic force.</s><s>Both substances showed a dose-dependent increase in diastolic force compared to baseline with comparable kinetics of the curves.</s><s>Results from the FFR in ventricular nonfailing human myocardium are presented in the supplement (Supplementary Figure <ref type="figure" target="#fig_1">2A-2D</ref>).</s><s>As observed in the FFR protocol in atrial trabeculae, strophanthidin and istaroxime exerted similar effects and no arrhythmic events could be detected for istaroxime or strophanthidin in any experiments.</s><s>Consistent with the findings in atrial myocardium, the RT50% was not different between Oncotarget 49267 www.impactjournals.com/oncotarget</s><s>istaroxime and strophanthidin in neither the DRR nor in the FFR experiments (Supplementary Figure <ref type="figure" target="#fig_2">3D-3F</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional effects of istaroxime and strophanthidin in failing ventricular myocardium from patients diagnosed with Tetralogy of Fallot</head><p><s>After testing the effects of istaroxime and strophanthidin in atrial and ventricular nonfailing trabeculae, we had the unique opportunity to measure inotropic response in failing ventricular trabeculae isolated from patients diagnosed with Tetralogy of Fallot (ToF).</s><s>ToF is the most frequent cyanotic congenital heart defect.</s><s>The anatomic abnormalities of ToF, such as interventricular communication, subpulmonary stenosis, biventricular origin of the aortic valve, and right ventricular hypertrophy cause right ventricular restrictive physiology and impaired relaxation <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref>.</s><s>Figure <ref type="figure" target="#fig_1">2</ref> shows the effects of istaroxime (n = 11 trabeculae) versus strophanthidin (n = 8 trabeculae) on developed force (Figure <ref type="figure" target="#fig_1">2A</ref>), diastolic force (Figure <ref type="figure" target="#fig_1">2B</ref>) and RT50% (Figure <ref type="figure" target="#fig_1">2C</ref>).</s><s>Both substances exhibited dose-dependent positive inotropic effects with a maximal inotropic effect at 0.3 µM.</s><s>Consistent with our findings from nonfailing atrium and ventricle, continuing to increase the concentration reversed the effects of both substances in the failing myocardium.</s><s>Diastolic force (Figure <ref type="figure" target="#fig_1">2B</ref>) and RT50% (Figure <ref type="figure" target="#fig_1">2C</ref>) did not change with istaroxime or strophanthidin administration.</s><s>An FFR protocol was not performed since the number of acquired trabeculae from the ToF tissue was too little for an experimental series.</s><s>No arrhythmic events were observed in any of the experiments performed using failing ventricular myocardium.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Istaroxime exerts stronger maximal positive inotropic effects than strophanthidin in failing myocardium (ToF)</head><p><s>In order to better compare the inotropic effects caused by strophanthidin and istaroxime, we used the data from the DRR for atrial, nonfailing ventricular, and failing ventricular trabeculae to focus on the maximal developed force, regardless of the concentration at which the maximum was reached.</s><s>Figure <ref type="figure" target="#fig_2">3</ref> shows box plots of the maximal developed force and of the corresponding diastolic force, respectively.</s><s>The analysis revealed a significant difference in the respective influence of istaroxime and strophanthidin on maximal developed force in failing hearts (Figure <ref type="figure" target="#fig_2">3E</ref>).</s><s>The maximal developed force in failing trabeculae was significantly higher in the istaroxime group than in the strophanthidin group (283% ± 26% of baseline vs. 186% ± 21% of baseline, p = 0.009).</s><s>The diastolic force measured at the time of maximal developed force did not differ between istaroxime and strophanthidin (Figure <ref type="figure" target="#fig_2">3F</ref>).</s><s>We did not observe significant differences in the maximal developed force between drugs in neither atrial (Figure <ref type="figure" target="#fig_2">3A-3B</ref>) nor nonfailing ventricular (Figure <ref type="figure" target="#fig_2">3C</ref>-3D) trabeculae.</s><s>The same analyses were performed on data obtained from FFR experiments.</s><s>Increasing stimulation frequencies did not reveal any significant differences between istaroxime and strophanthidin on maximal developed force, diastolic force or RT50% in atrial or nonfailing ventricular myocardium (Supplementary Figure <ref type="figure">4A-4F</ref>).</s><s>Thus, istaroxime exerts stronger maximal positive inotropic effects than strophanthidin in failing ventricular myocardium.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>Our major findings are: (1) istaroxime has positive inotropic effects in human atrial, human nonfailing ventricular, and human failing ventricular myocardium;</s></p><p><s>(2) istaroxime and strophanthidin show comparable effects with respect to dose response (DRR) and force-frequency relationship (FFR); (3) istaroxime has stronger maximal positive inotropic effects than strophanthidin in failing human myocardium.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional and toxic effects of istaroxime and strophanthidin in human myocardium</head><p><s>The DRR that was performed to compare the effects of strophanthidin and istaroxime on the developed force in human atrial, nonfailing ventricular, and failing ventricular trabeculae (ToF) showed that increased concentrations of istaroxime as well as strophanthidin resulted in a positive inotropic response.</s><s>Supraphysiological concentrations of istaroxime and strophanthidin exhibited a toxic effect causing a decline in developed force.</s><s>These results are similar to what has previously been reported on the effects of istaroxime in murine ventricular myocytes, where cell shortening (inotropy) was investigated in a concentrationdependent fashion <ref type="bibr" target="#b25">[26]</ref>.</s><s>Chronic istaroxime has also been shown to improve cardiac function and heart rate variability in hamster cardiomyopathy models <ref type="bibr" target="#b26">[27]</ref>.</s><s>In our study, both istaroxime and strophanthidin slightly increased diastolic force in a dose-dependent manner compared to baseline with comparable curve kinetics in atrial and nonfailing ventricular myocardium.</s><s>Overall, strophanthidin and istaroxime had similar functional effects in human atrial, nonfailing and failing ventricular myocardium.</s><s>The similarities in the DRR and FFR were unexpected, especially when considering the mechanistic effects of istaroxime <ref type="bibr" target="#b27">[28]</ref>, and taking into account the fact that istaroxime is significantly less pro-arrhythmic than digoxin <ref type="bibr" target="#b25">[26]</ref>.</s><s>In our experiments, neither strophanthidin nor istaroxime treatment resulted in any detected arrhythmic events, even at high concentrations of both substances and high Ca 2+ concentrations (2.5 mM) used in all experiments.</s><s>This data implicates a comparable safety profile for istaroxime with respect to other NKA inhibitors.</s><s>www.impactjournals.com/oncotarget</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effects of istaroxime in an in-vitro model of heart failure</head><p><s>We had initially hypothesized that additional SERCA2a stimulation would be beneficial, especially when relaxation is impaired, such as in the conditions of our ToF HF model.</s><s>Interestingly, SERCA2a stimulation by istaroxime did not reduce diastolic force or accelerate RT50% in any of our tested tissues.</s><s>However, our analysis revealed that the maximal developed force in failing ventricular trabeculae was significantly higher when treated with istaroxime compared to strophanthidin.</s><s>This difference did not occur in atrial or in nonfailing ventricular trabeculae.</s><s>The positive inotropic effect of both compounds is mediated through NKA inhibition, with subsequent increase of intracellular Ca 2+ .</s><s>Our findings in atrial and nonfailing ventricular myocardium suggest istaroxime and strophanthidin inhibit the NKA to a similar extent.</s><s>The exact extent of NKA inhibition by istaroxime compared to strophanthidin has never been quantified.</s><s>Since ToF is a condition with impaired relaxation and restrictive right ventricular physiology <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b28">29]</ref>, we can only speculate that the additional SERCA2a stimulation by istaroxime in a setting of impaired relaxation is responsible for a more pronounced increase in maximal developed force.</s><s>We conclude that in our in-vitro model of HF, istaroxime has stronger maximal positive inotropic effects than strophanthidin.</s><s>This is in line with the results of experiments using a canine model of acute myocardial infarction where istaroxime had a greater effect on contractility than dobutamine and also improved relaxation, while dobutamine did not <ref type="bibr" target="#b29">[30]</ref>.</s></p><p><s>Our in-vitro DRR findings further complement the findings from the HORIZON-HF trial, where istaroxime was tested in acute heart failure syndromes using a comprehensive assessment of cardiovascular function in addition to hemodynamic measurements <ref type="bibr" target="#b30">[31]</ref>.</s><s>Other studies performed in dogs with advanced heart failure showed istaroxime significantly increased LV ejection fraction in a dose-dependent manner.</s><s>In addition, istaroxime significantly reduced LV end-diastolic pressure and end-diastolic wall stress <ref type="bibr" target="#b14">[15]</ref>.</s><s>The latter effect contradicts with our findings.</s><s>Another phase 1-2 doseescalating study evaluating the safety and tolerability of istaroxime suggested that istaroxime is potentially useful in the treatment of HF <ref type="bibr" target="#b31">[32]</ref>.</s><s>We found only one report on the effects of istaroxime using myocardial trabeculae from patients undergoing cardiac transplantation <ref type="bibr" target="#b32">[33]</ref>.</s><s>In that study, istaroxime (100 nM -1.0 µM) increased developed tension and twitch kinetics in a dose-dependent manner while stimulating SERCA2a activity in sarcoplasmic reticulum microsomes at physiological free calcium concentrations.</s><s>Istaroxime is currently the only compound available that stimulates SERCA2a activity and produces a luso-inotropic effect in HF <ref type="bibr" target="#b32">[33]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NKA inhibition in heart failure and potential link to prostate cancer</head><p><s>Classical inotropic agents, such as beta1-adrenergic agonists, phosphodiesterase III inhibitors and Ca 2+ sensitizers improve HF symptoms and hemodynamics by increasing the levels of free intracellular Ca 2+ and thus contractility, but also increase myocardial oxygen demand and exert arrhythmogenic effects <ref type="bibr" target="#b34">[34]</ref>.</s><s>Despite the acute hemodynamic benefits, these inotropes play no role in the management of chronic advanced HF due to inherent adverse side-effect profiles <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b35">35]</ref>.</s><s>Instead, a very well established protocol of therapeutic escalation levels is given in the European Society of Cardiology (ESC) heart failure guidelines <ref type="bibr" target="#b36">[36]</ref>.</s><s>NKA inhibitors may provide additional help in treatment with a class of recommendation IIb and a level of evidence B. This low class of recommendation is due to the potential harmful effects of digoxin for women <ref type="bibr" target="#b37">[37]</ref> and controversial reported effects in meta-analysis for both digoxin and digitoxin <ref type="bibr" target="#b38">[38]</ref><ref type="bibr">[39]</ref><ref type="bibr" target="#b40">[40]</ref>.</s><s>In summary, NKA inhibition does not lower mortality but does seem to lower the incidence of decompensation of heart failure and the hospitalization rate for heart failure.</s><s>Of note, istaroxime is not currently featured as an established approach in the ESC guidelines for heart failure.</s><s>However, the reported negative effects for women caused by the NKA inhibitor digoxin are not an issue in terms of its use as a PC treatment.</s><s>Keeping in mind that HF can develop as a side effect of hormonal therapy in PC, the additional use of inotropes could be beneficial.</s><s>Moreover, istaroxime itself exerts PC inhibiting effects.</s><s>The median age of PC patients at time of diagnosis is 66 years.</s><s>HF patients, especially those diagnosed with Heart Failure with preserved Ejection Fraction (HFpEF), are also usually at an advanced age <ref type="bibr" target="#b41">[41]</ref>.</s><s>HFpEF accounts for about 50% of all cases of HF <ref type="bibr" target="#b42">[42]</ref><ref type="bibr" target="#b43">[43]</ref><ref type="bibr" target="#b44">[44]</ref> and its prevalence relative to Heart Failure with reduced Ejection Fraction (HFrEF) is growing by 10% per decade <ref type="bibr" target="#b44">[44]</ref>.</s><s>The vast majority of published reports assessing the effects of istaroxime focused on preclinical HFrEF models and HFrEF patients.</s><s>We tested istaroxime in a novel in-vitro HF model with diastolic impairment, which is a hallmark of HFpEF, and demonstrated that istaroxime exerts stronger maximal inotropic effects compared to strophanthidin.</s></p><p><s>The presented information suggests that istaroxime has the potential to be a beneficial add-on therapy for PC, exerting direct anti-cancer effects and counteracting potential side effects of the basic therapy with respect to toxic effects at supraphysiological concentrations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations and strengths of the study</head><p><s>Compared to established animal models that mimic heart failure, our HF model is not a classic experimental model of heart failure with preserved or reduced ejection fraction.</s><s>However, the use of human tissue for all experiments enhances the translational nature of our findings.</s><s>The study is clearly limited by the small number of ToF patients as a source of failing ventricular trabeculae, resulting in a rather small number of experiments.</s></p><p><s>We did not directly dissect the inhibitory effect on the NKA from the stimulatory effect on SERCA2a.</s><s>However via comparison to the NKA inhibitor strophanthidin, which has no known SERCA2a stimulatory effect, our results suggest that SERCA2a stimulation plays a role.</s><s>To the best of our knowledge, no study has attempted to determine which SERCA isoform is primarily expressed in ventricular ToF myocardium.</s><s>This is relevant since istaroxime is effective on the SERCA2a www.impactjournals.com/oncotarget</s><s>isoform in the presence of phospholamban, but not on the SERCA1 alone <ref type="bibr" target="#b45">[45]</ref>.</s></p><p><s>On the other hand, the strength of this study is that it was performed in human tissue and carefully assessed the effects of istaroxime and strophanthidin in atrial, nonfailing, and failing ventricular myocardium.</s><s>Our HF model is of high value, yet no single model can entirely reflect the complexity of heart failure as a clinical syndrome.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head><p><s>We assessed three different types of human cardiac tissue: right atrial appendages, nonfailing left ventricles, and right ventricles from infants diagnosed with Tetralogy of Fallot (ToF).</s><s>The ToF tissue served as a heart failure model.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human myocardium and trabeculae preparation</head><p><s>Right atrial appendages were obtained from hearts of patients (n = 22 patients) undergoing cardiac surgery for aortocoronary bypass or valve replacement.</s><s>Left ventricular trabeculae were obtained from human nonfailing donor hearts (n = 8 hearts) that were not suitable for transplantation.</s><s>ToF right ventricular tissue, which was considered the failing sample, was obtained during the surgical reconstruction procedure of the right ventricular outflow tract (n = 9 patients).</s><s>The study was approved by the local ethics committee and patients gave informed written consent.</s><s>Endocardial trabeculae were prepared in cardioprotective solution, as described in the supplement.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experimental protocol</head><p><s>Trabeculae were gradually stretched to the length at which maximal force development was achieved (baseline).</s><s>After recording a steady state at baseline, we performed two different protocols, a dose response relationship (DRR) and a force frequency relationship (FFR).</s><s>For the DRR, trabeculae were exposed to increasing concentrations of either istaroxime or strophanthidin (10 nM to 1 µM).</s><s>After 30 minutes of incubation and reaching steady-state conditions, developed force, diastolic force, and RT50% were recorded.</s><s>Then the next concentration step was performed.</s><s>Moreover, we performed FFR by increasing stimulation frequency stepwise from 0.5 Hz to 3.0 Hz.</s><s>Upon reaching a steady state, kinetic parameters were recorded, and FFR was repeated in the presence of 0.1 µM istaroxime or strophanthidin.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drugs</head><p><s>Istaroxime was provided by SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A., Rome -Italy and strophanthidin was purchased from Calbiochem.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>For each separate group (atrium, nonfailing ventricle, failing ventricle), we performed a repeated measures analysis of variance (rmANOVA) with all data rank transformed.</s><s>P-values for contrasts were corrected for multiple comparisons according to Bonferroni.</s><s>Differences in maximum were assessed with the Wilcoxon rank sum test.</s><s>P-values less than 0.05 were considered statistically significant.</s><s>All computations were done using IBM SPSS Statistics (Release 21.0.0.0 2012.</s><s>Armonk, NY, USA).</s><s>Detailed statistical analysis is provided in the supplement.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS</head><p><s>This is the first report of the functional effects of istaroxime on human myocardium under conditions similar to HF.</s><s>We found close similarities between istaroxime and strophanthidin in their effect on systolic force, diastolic force, and relaxation time in nonfailing tissue.</s><s>However, using ToF as a model of heart failure, istaroxime showed stronger maximal positive inotropic effects than strophanthidin.</s><s>Combining our in-vitro results with potential PC inhibiting effects, istaroxime may provide a new therapeutic option for conservative management of PC that counteracts harmful side effects of current therapy strategies and merits further investigation of its clinical use.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc><div><p><s>Figure 1: Inotropic effects of istaroxime and strophanthidin on human atrial and nonfailing ventricular myocardium.</s><s>Comparable effects of istaroxime and strophanthidin on developed and diastolic force in human atrial (A-B) and nonfailing ventricular (C-D) myocardium.</s><s>Data are represented as mean +/− SEM.</s><s>(A) Dose response relationship (DRR) for strophanthidin (open circles; n = 13 trabeculae) and istaroxime (filled circles; n = 8 trabeculae).</s><s>Effect on developed force: * = p &lt; 0.05 vs. baseline (strophanthidin); # = p &lt; 0.05 vs. baseline (istaroxime).</s><s>(B) DRR for strophanthidin (open circles) and istaroxime (filled circles) with effect on diastolic force; # = p &lt; 0.05 vs. baseline (istaroxime).</s><s>(C) DRR for strophanthidin (open circles; n = 9 trabeculae) and istaroxime (filled circles; n = 9 trabeculae).</s><s>Effect on developed force: * = p &lt; 0.05 vs. baseline (strophanthidin); # = p &lt; 0.05 vs. baseline (istaroxime).</s><s>(D) DRR for strophanthidin (open circles) and istaroxime (filled circles) with effect on diastolic force: # = p &lt; 0.05 vs. baseline (istaroxime).</s></p></div></figDesc><graphic coords="3,116.32,250.45,379.35,385.26" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 :</head><label>2</label><figDesc><div><p><s>Figure 2: Inotropic effects of istaroxime and strophanthidin on human ventricular myocardium from patients with Tetralogy of Fallot (ToF).</s><s>Comparable effects of istaroxime and strophanthidin on developed force, diastolic force, and RT50% in ventricular myocardium from infants with Tetralogy of Fallot (ToF).</s><s>Data are represented as mean +/− SEM.</s><s>(A) Dose response relationship (DRR) for strophanthidin (open circles; n = 8 trabeculae) and istaroxime (filled circles; n = 11 trabeculae).</s><s>Effect on developed force: * = p &lt; 0.05 vs. baseline (strophanthidin): # = p &lt; 0.05 vs. baseline (istaroxime).</s><s>(B) DRR for strophanthidin (open circles) and istaroxime (filled circles) with effect on diastolic force.</s><s>(C) DRR for strophanthidin (open circles; n = 8 trabeculae) and istaroxime (filled circles; n = 11 trabeculae) with effect on RT50% (% of baseline).</s></p></div></figDesc><graphic coords="5,181.78,50.40,248.44,587.33" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: Maximal inotropic effect (istaroxime vs. strophanthidin).</s><s>Istaroxime enhances maximum developed force in failing trabeculae more than strophanthidin, but not maximum diastolic tension.</s><s>Data are represented as mean +/− SEM.</s><s>(A) Box plot comparing maximum developed force values of strophanthidin (n = 8 trabeculae) and istaroxime (n = 13 trabeculae), regardless of the concentration at which maximum developed force was reached, in atrium (% of baseline).</s><s>(B) Box plot comparing diastolic force values (corresponding values to (A) of strophanthidin (n = 8 trabeculae) and istaroxime (n = 13 trabeculae) in atrium (mN/mm 2 ).</s><s>(C) Box plot comparing maximum developed force values of strophanthidin (n = 9 trabeculae) and istaroxime (n = 9 trabeculae) in nonfailing ventricle (% of baseline).</s><s>(D) Box plot comparing diastolic force values (corresponding values to (C) of strophanthidin (n = 9 trabeculae) and istaroxime (n = 9 trabeculae), in nonfailing ventricle (mN/mm 2 ).</s><s>(E) Box plot comparing maximum developed force values of strophanthidin (n = 8 trabeculae) and istaroxime (n = 11 trabeculae) in failing ventricle (% of baseline): # = p &lt; 0.05.</s><s>(F) Box plot comparing diastolic force values (corresponding values to (E) of strophanthidin (n = 8 trabeculae) and istaroxime (n = 11 trabeculae) in failing ventricle (mN/mm 2 ).</s><s>° = outliers, * = extreme outliers.</s></p></div></figDesc><graphic coords="6,108.31,146.90,395.37,450.00" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">www.impactjournals.com/oncotarget</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>Istaroxime was provided by SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A., Rome -Italy.</s><s>We thank Friederike von Lewinski, MD, PhD for her contribution to the study design and planning.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations</head><p><s>DRR: dose-response relationship; ESC: European Society of Cardiology; FFR: force-frequency relationship; HF: heart failure; NKA: Na + -K + -ATPase; PC: prostate cancer; RT50%: time from contraction peak to 50% relaxation; SEM: standard error of the mean; SERCA2a: sarco/endoplasmic reticulum Ca 2+ -ATPase 2a; ToF: Tetralogy of Fallot.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head><p><s>D.v.L., M.W., M.Kh., and B.P. designed research; M.W., A.V., and E.K. performed research; D.v.L., M.W., P.P.R., and M.Kh.</s><s>analyzed data; M.Kh., E.K., M.P., and D.E. wrote the manuscript; G.S. performed statistical analysis; I.K., P.C., and M.Kö.</s><s>provided ToF material and data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICTS OF INTEREST</head><p><s>The authors declare that there is no conflicts of interest regarding the publication of this paper.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FUNDING</head><p><s>The presented work had no funding.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer Statistics</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
		<idno type="DOI">10.3322/caac.21387</idno>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="7" to="30" />
			<date type="published" when="2017">2017. 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Screening and prostate-cancer mortality in a randomized European study</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Schroder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hugosson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Roobol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Tammela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ciatto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Nelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kwiatkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lujan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lilja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zappa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Denis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Recker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berenguer</surname></persName>
		</author>
		<idno>doi: 10.1056/ NEJMoa0810084</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="page" from="1320" to="1328" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Trends in the Incidence of Fatal Prostate Cancer in the United States by Race</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Andreotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Younes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Cleary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Cook</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2016.05.011</idno>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="195" to="201" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Cancer Stat Facts: Prostate Cancer. National Cancer Institute</title>
		<ptr target="http://seer.cancer.gov/statfacts/html/prost.html" />
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>The Surveillance, Epidemiology, and End Results Program</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Cornford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bellmunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Briers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Santis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Joniau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Lam</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Van Der Poel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Van Der Kwast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Rouviere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2016.08.002</idno>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="630" to="642" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Braccioforte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Moran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'amico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename></persName>
		</author>
		<idno type="DOI">10.1001/jama.2009.1137</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">302</biblScope>
			<biblScope unit="page" from="866" to="873" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Keating</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>O'malley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Freedland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Smith</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djp404</idno>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="39" to="46" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care</title>
		<author>
			<persName><forename type="first">E</forename><surname>Martin-Merino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Johansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Garcia</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename></persName>
		</author>
		<idno type="DOI">10.2165/11594540-000000000-00000</idno>
	</analytic>
	<monogr>
		<title level="j">Drug Saf</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1061" to="1077" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Morgia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Russo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tubaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bortolus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Randone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gabriele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Trippa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zattoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Porena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mirone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Serni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Nero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.urology.2016.06.024</idno>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="165" to="170" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Shore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Villers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Siemens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Phung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Os</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hasabou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhattacharya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Heidenreich</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(15)00518-5</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="153" to="163" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Cardiac inotropes: current agents and future directions</title>
		<author>
			<persName><forename type="first">G</forename><surname>Hasenfuss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Teerlink</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehr026</idno>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1838" to="1845" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?</title>
		<author>
			<persName><forename type="first">U</forename><surname>Campia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nodari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11897-010-0021-9</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Heart Fail Rep</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="100" to="109" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Ambrosy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ferrandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferrari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Discov Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="141" to="151" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?</title>
		<author>
			<persName><forename type="first">H</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Blair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Harinstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Sabbah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Porchet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<idno>doi: 10.1007/ s10741-009-9136-z</idno>
	</analytic>
	<monogr>
		<title level="j">Heart Fail Rev</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="277" to="287" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Hemodynamic properties of a newgeneration positive luso-inotropic agent for the acute treatment of advanced heart failure</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Sabbah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Imai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cowart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Carminati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amjcard.2006.09.005</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="41A" to="46A" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">HORIZON-HF Investigators. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Blair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Macarie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ruzyllo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Korewicki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Bubenek-Turconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ceracchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bianchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Carminati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kremastinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Sabbah</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jacc.2008.03.015</idno>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="2276" to="2285" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor</title>
		<author>
			<persName><forename type="first">K</forename><surname>Alevizopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dimas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Papadopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tsapara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Alkahtani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Honisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Prousis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Alarifi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Calogeropoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stournaras</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.8329</idno>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="24415" to="24428" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Na+/K+ ATPase inhibitors in cancer</title>
		<author>
			<persName><forename type="first">K</forename><surname>Alevizopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Calogeropoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stournaras</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Drug Targets</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="988" to="1000" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Is digoxin use for cardiovascular disease associated with risk of prostate cancer?</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Hansten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Stanford</surname></persName>
		</author>
		<idno type="DOI">10.1002/pros.22733</idno>
	</analytic>
	<monogr>
		<title level="j">Prostate</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="97" to="102" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Steroidal cardiac Na+/K+ ATPase inhibitors exhibit strong anti-cancer potential in vitro and in prostate and lung cancer xenografts in vivo</title>
		<author>
			<persName><forename type="first">K</forename><surname>Dimas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Papadopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baskakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Prousis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tsakos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Alkahtani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Honisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Calogeropoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Alevizopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stournaras</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Agents Med Chem</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="762" to="770" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Statins and prostate cancer risk: a case-control study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Shannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tewoderos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Garzotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Beer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Derenick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Palma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Farris</surname></persName>
		</author>
		<idno type="DOI">10.1093/aje/kwi203</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="318" to="325" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Platz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Till</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Parnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Figg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Albanes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Neuhouser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Thompson</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Kristal</surname></persName>
		</author>
		<idno type="DOI">10.1158/1055-9965.EPI-09-0472</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol Biomarkers Prev</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="2807" to="2813" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Mechanistic insight into the functional and toxic effects of Strophanthidin in the failing human myocardium</title>
		<author>
			<persName><forename type="first">D</forename><surname>Von Lewinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bisping</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Elgner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kockskamper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pieske</surname></persName>
		</author>
		<idno>doi: 10.1016/j. ejheart.2007.08.004</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1086" to="1094" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Anatomophysiologic basis of tetralogy of Fallot and its clinical implications</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Duro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Moura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Leite-Moreira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Port Cardiol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="591" to="630" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Impact of restrictive physiology on intrinsic diastolic right ventricular function and lusitropy in children and adolescents after repair of tetralogy of Fallot</title>
		<author>
			<persName><forename type="first">C</forename><surname>Apitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Latus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Binder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Uebing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bretschneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sieverding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hofbeck</surname></persName>
		</author>
		<idno type="DOI">10.1136/hrt.2010.203190</idno>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="1837" to="1841" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Alemanni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rocchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Re</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zaza</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.yjmcc.2011.02.008</idno>
	</analytic>
	<monogr>
		<title level="j">J Mol Cell Cardiol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="910" to="918" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters</title>
		<author>
			<persName><forename type="first">P</forename><surname>Lo Giudice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Mattera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Gagnol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Borsini</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10557-011-6283-y</idno>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Drugs Ther</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="133" to="138" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Intracellular dyssynchrony of diastolic cytosolic [Ca(2)(+)] decay in ventricular cardiomyocytes in cardiac remodeling and human heart failure</title>
		<author>
			<persName><forename type="first">F</forename><surname>Hohendanner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ljubojevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Macquaide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sacherer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sedej</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Biesmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wakula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Platzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sokolow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Herchuelz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Antoons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sipido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pieske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Heinzel</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCRESAHA.113.300895</idno>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="527" to="538" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Right ventricular diastolic function after repair of tetralogy of Fallot</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Sachdev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bhagyavathy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Varghese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Coelho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Kumar</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00246-005-1186-y</idno>
	</analytic>
	<monogr>
		<title level="j">Pediatr Cardiol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="250" to="255" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Sympathomimetic inefficiency in restoring contractility in the acute or chronic beta-blocker-treated ischaemic heart: comparison with a new agent</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Mattera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vanoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Gagnol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Loi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Borsini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Carminati</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejheart.2008.07.007</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="990" to="996" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Blair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Macarie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ruzyllo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bacchieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bianchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Pang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Harinstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Sabbah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<author>
			<persName><surname>Horizon-Hf</surname></persName>
		</author>
		<author>
			<persName><surname>Investigators</surname></persName>
		</author>
		<idno type="DOI">10.1097/MJT.0b013e31816d9186</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Ther</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="231" to="240" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Ghali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Torre-Amione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Haynos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Rayburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cowart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Carminati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amjcard.2006.09.006</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="47A" to="56A" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Micheletti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Palazzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Giacalone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ferrandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schiavone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Moro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Parodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bianchi</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure</title>
		<idno type="DOI">10.1016/j.amjcard.2006.09.003</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="24A" to="32A" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Investigational positive inotropic agents for acute heart failure</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tamargo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Caballero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Amoros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Delpon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Hematol Disord Drug Targets</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="193" to="205" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Inotropic therapy for end-stage heart failure patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Toma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Starling</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11936-010-0090-9</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Treat Options Cardiovasc Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="409" to="419" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Voors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Cleland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Falk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Gonzalez-Juanatey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Harjola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Jankowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Linde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nihoyannopoulos</surname></persName>
		</author>
		<idno type="DOI">10.1002/ejhf.592</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="891" to="975" />
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
	<note>Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Adams</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Gattis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Gheorghiade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.jacc.2005.02.091</idno>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="497" to="504" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Hood</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Dans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jaeschke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Mcmurray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Card Fail</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="155" to="164" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Digoxin-associated mortality: a systematic review and meta-analysis of the literature</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vamos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Erath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Hohnloser</surname></persName>
		</author>
		<idno>doi: 10.1093/ eurheartj/ehv143</idno>
		<ptr target="www.impactjournals.com/oncotarget39" />
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1831" to="1838" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">J</forename><surname>Ziff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Lane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Samra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Griffith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kirchhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Steeds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Townend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kotecha</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.h4451</idno>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="page">4451</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Fonarow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Stough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Albert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Greenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Yancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename></persName>
		</author>
		<idno>doi: 10.1016/j. jacc.2007.04.064</idno>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="768" to="777" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Gurwitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Magid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Mcmanus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Saczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Thorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Go</surname></persName>
		</author>
		<idno>doi: 10.1016/j. amjmed.2012.10.022</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="393" to="400" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Systolic and diastolic heart failure in the community</title>
		<author>
			<persName><forename type="first">F</forename><surname>Bursi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Weston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Redfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Jacobsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pakhomov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">T</forename><surname>Nkomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Meverden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Roger</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.296.18.2209</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="page" from="2209" to="2216" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Trends in prevalence and outcome of heart failure with preserved ejection fraction</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Owan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">O</forename><surname>Hodge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Herges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Jacobsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Roger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Redfield</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa052256</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="251" to="259" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ferrandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tadini-Buoninsegni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bartolommei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Molinari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Tripodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Moncelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bianchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferrari</surname></persName>
		</author>
		<idno type="DOI">10.1111/bph.12278</idno>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="1849" to="1861" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
